Taisho To Go Private To Aid 'Dynamic' Restructuring, R&D Investment
$4.8bn MBO Japan's Largest
The largest shareholder in major Japanese pharma firm Taisho, the founding Uehara family, intends to smooth the way to the restructuring and expansion of the business by acquiring and delisting all of its stock. The nearly $5bn size of the deal would makes it the biggest management buyout in Japanese corporate history.
You may also be interested in...
Taisho's Self-Medication business posted a solid gain in the six months ended 30 September as a recovery in its Overseas operation boosted a flat performance in Japan.
Strength in its overseas consumer health business, particularly in Asia, helped Taisho offset falling sales at home due to the impact of the COVID-19 pandemic in its latest nine-month reporting period.
TOKYO - Taisho Pharmaceutical Co. Ltd., Japan's largest OTC manufacturer, carved out an entry in Southeast Asia with energy drink series Lipovitan, and now the company is looking to maximize its 2009 acquisition of Bristol-Myers Squibb Co.'s Asian OTC subsidiary through distribution channels from an acquisition of Malaysia's largest domestic pharmaceutical company